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Abstract 
Many patients with a history of breast cancer (BC) will suffer from vasomotor symptoms, which can be induced 
or exacerbated by treatment with tamoxifen or aromatase inhibitors. The LIBERATE trial was designed as a 
randomized, double-blind, multicenter trial to demonstrate that tibolone 2.5mg/day (Livial®) is non-inferior to 
placebo regarding BC recurrence in women with vasomotor symptoms surgically treated for primary BC within 
the last 5 years. Secondary objectives are effects on vasomotor symptoms as well as overall survival, bone 
mineral density and health-related quality of life. 
Mean age at randomization was 52.6 years, and the mean time since surgery was 2.1 years. The mean daily 
number of hot flushes and sweating episodes was 7.3 and 6.1, respectively. For the primary tumor, Stage IIA or 
higher was reported for > 70% of the patients. In subjects whose receptor status was known, 78.2% of the tumors 
were estrogen receptors positive. At randomization, tamoxifen was given to 66.2% of all patients and aromatase 
inhibitors to 7%. Chemotherapy was reported by 5% at randomization. 
The adjuvant tamoxifen use in LIBERATE allows a comparison with the Stockholm trial (showing no risk of BC 
recurrence associated with hormone therapy), which was stopped prematurely subsequent to HABITS. The 
LIBERATE trial is the largest, ongoing, well-controlled study for treatment of vasomotor symptoms in BC 
patients. 
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Breast cancer is the most common malignancy in Western women. Treatment for early breast cancer has become 
highly effective, but at the price of severe side effects. A substantial proportion of patients will suffer from 
vasomotor symptoms, which result directly from adjuvant treatment with tamoxifen or aromatase inhibitors1,2 or 
other treatment modalities such as ovarian suppression or ablation and chemotherapy.3,4
Hormone therapy (HT) containing estrogen is effective, but considered unsafe.5 The concern for an increased 
risk of breast cancer in healthy women taking postmenopausal HT6-8 has generally conventionally led to a 
contraindication for HT in women with a history of breast cancer, despite findings of observational studies that 
the risk of recurrence in breast cancer survivors is not increased with HT use.9,10 Non-hormonal therapy for 
severe motor symptoms is not effective.5
Tibolone is a synthetic steroid with a clinical profile that differs from that of both classical estrogen-based HT, as 
well as from that of selective estrogen receptor modulators (SERMs).13,14 Tibolone has shown its efficacy in 
reducing climacteric symptoms both in healthy menopausal women,15 as well as in women receiving tamoxifen16 
or GnRH analogs17 after surgery for breast cancer. The mode of action of tibolone differs from that of 
conventional estrogen receptor ligands. Tibolone has been classified as a selective tissue estrogenic activity 
regulator (STEAR),18 a substance that has different clinical effects on different tissues due to tissue-selective 
metabolism and enzyme regulation. After oral administration of tibolone, three active metabolites are formed. 
The two estrogenic metabolites, 3α-OH and 3β-OH-tibolone, have been shown to have beneficial effects on 
vasomotor symptoms, the vagina and bone.19 The third metabolite, the delta-4-isomer, has progestogenic 
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properties and is locally produced within the endometrium and therefore minimizes vaginal bleeding.19,20 In the 
breast, tibolone and its metabolites reduce sulfatase21 and stimulate sulfotransferase activity22 thereby inhibiting 
the formation of active estrogenic substances (including the 3-OH metabolites of tibolone) and promoting the 
formation of inactive estrogens.23,24 Currently available clinical observations with tibolone suggest that it does 
not increase mammographic breast density and causes less breast tenderness than combined estrogen-
progestogen therapy does.14 Tibolone in a dose of 2.5mg/day has been registered (as Livial®) in 90 countries for 
treatment of climacteric symptoms and in 45 of these countries for the prevention of osteoporosis. It has been 
judged to have a good overall clinical tolerability and it does not seem to increase breast density on the 
mammogram.14
A few pilot studies have investigated the feasibility to use tibolone as add back in breast cancer patients. In a 
double-blind, randomized, placebo-controlled study in 70 postmenopausal women receiving tamoxifen following 
surgery for early breast cancer, tibolone was more effective than placebo in reducing hot flashes. There were no 
recurrences in either group during the 12-month study.16 Although these findings are promising, definitive safety 
data can only come from a large, long-term controlled clinical trial such as the LIBERATE (livial intervention 
following breast cancer: efficacy, recurrence and tolerability endpoints) study. As tibolone has been increasingly 
prescribed preferentially in disease-free breast cancer patients who persistently seek help for their often disabling 
menopausal complaints,25 such a trial is highly warranted. 
The (LIBERATE) study was designed to investigate the safety and efficacy of 2.5mg/day oral tibolone in women 
with vasomotor symptoms and a history of breast cancer in the previous 5 years. 
In this paper, we describe the design and rationale of the LIBERATE study, together with the baseline 
characteristics of the patients enrolled in the study and discuss the potential of the LIBERATE study to provide 




The LIBERATE study is a randomized, placebo-controlled, double-blind, parallel-group study. The primary 
outcome of interest is breast cancer recurrence, defined here as loco-regional recurrence, and/or distant 
metastasis and/or new primary invasive tumor in the contralateral breast. The primary aim is to test the 
hypothesis that tibolone is non-inferior to placebo regarding breast cancer recurrence. 
Adequate sample size was estimated to be at least 3000 women ( > 1500 women in each arm) based on the 
assumption that breast cancer recurrence in the placebo group would be 15% after 3 years, assuming a yearly 
recurrence rate of 3% and 8% for node-negative and node-positive patients, respectively. The power was 
calculated to be 80.9% for a total sample size of 3100 subjects, provided that at least 1800 subjects were node 
positive. 
Study endpoints 
The primary outcome variable is breast cancer recurrence. Secondary study outcomes include vasomotor 
symptoms, bone mineral density (BMD), health-related quality of life (HRQL) and overall survival. All breast 
cancer recurrence events reported will be assessed in a blinded manner by an independent Adjudication 
Committee. 
Eligibility criteria 
Breast cancer patients with no evidence of disease were eligible for this study when they had been surgically 
treated within the previous 5 years for histological confirmed T1-3, N 0-2, M0 breast cancer irrespective of 
hormone receptor status. 
Subjects had to be younger than 75 years of age, with a last menstruation 12 months or more before (when not 
ovariectomized, hysterectomized or on GnRH analogs). Women had to have vasomotor symptoms, either related 
to natural menopause or resulting from prior or current adjuvant breast cancer treatment. Prior or current use of 
tamoxifen hydrochloride, aromatase inhibitors, GnRH analogs or chemotherapy was allowed. Current use of 
estrogenic or progestagenic substances was not allowed, neither was use of raloxifene hydrochloride.  Adjuvant 
breast cancer treatments were permitted during the trial. 
In all non-hysterectomized women, the endometrium was assessed by transvaginal ultrasound scan (TVUS). 
Endometrial polyps in tamoxifen users and a double endometrium thickness of more than 8 mm in non-
tamoxifen users led to exclusion. Non-tamoxifen users with a double endometrial thickness of more than 4 mm 
had to show inactive or atrophic endometrium in the biopsy. 
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Screening and randomization 
Screening started after a subject had signed the informed consent form. Data were collected on medical, 
gynecological, family and breast cancer history, demographics and previous medications. Following physical 
(including a breast examination and a mammogram) and gynecological examination (including a cervical PAP 
smear), TVUS was performed in all subjects at screening. 
Blood samples from non-fasting subjects were drawn for routine hematology and biochemistry; all blood 
samples were determined in one central laboratory. Eligible subjects were assigned to either tibolone 2.5 mg 
daily or placebo with a randomization ratio of 1:1. 
Follow-up assessments 
Follow-up visits were scheduled each half-year until a maximum of 5 years with an additional visit after the first 
3 months. At each follow-up visit, a physical examination and breast examination were performed; a vasomotor 
symptoms form completed and vital signs, concomitant medication, vaginal bleeding episodes and adverse 
events are documented. Gynecological examinations (including cervical smear), mammography and blood 
sampling for routine laboratory safety assessments were performed annually in all patients. An endometrial 
biopsy was performed in subjects with vaginal bleeding that persisted beyond the first 3 months or started after 
the first 3 months. If biopsies were categorized as any type of hyperplasia or cancer at any time during the study, 
the subject was discontinued from trial medication and treated. All women who discontinued trial medication 
were strongly encouraged to attend subsequent visits as scheduled in the protocol. All subjects were questioned 
about possible adverse events at each visit. 
Data analysis 
The analyses of the primary outcome variable will be performed upon an average study participation of at least 3 
years. The breast cancer recurrence hazard ratio of tibolone versus placebo will be estimated using survival 
analysis models fitted to the time to breast cancer recurrence data. Non-inferiority will be assessed by comparing 
the upper limit of the two-sided 95% confidence interval of the hazard ratio with the pre-specified non-inferiority 
margin. The analysis of the overall survival will use statistical techniques comparable to that of the primary 
outcome measure. 
Results 
The LIBERATE study protocol has been approved by the Independent Ethics Committee or the Institutional 
Review Board at each participating center. Written informed consent was obtained from all study participants. 
Screening and randomization 
Potential participants were recruited from the investigators practices, referrals from clinical staff and by other 
local initiatives, depending on the clinic's preference and the local regulations. The recruitment phase started on 
20 June 2002 and finished on 10 December 2004. A total of 3583 women were screened, of whom 3148 were 
eligible. Women were randomized in 245 centers in 31 countries. 
Baseline characteristics of women included 
The baseline characteristics of the study population are shown in Tables 1 and 2, and in Figs. 1 and 2. As per the 
database status on 5 January 2007, the mean age at randomization was 52.6 years. The large majority of 
women (81.2%) was between 40 and 60 years of age, with 40.7% being younger than 50 years. Nearly 80% was 
Caucasian. Mean weight was 70.5 kg and mean body mass index 27.0 kg/m2. 
Breast cancer surgery had been breast sparing in only 42.8% of all women and mean time since surgery was 2.1 
years. A pathological tumor size of > 2.0 cm (T2/3) was reported for 44.9% of the patients and a node-positive 
status (N1/2) for 57.8%, resulting in > 70% of Stage IIA or higher for the primary tumor. Of the patients with a 
known receptor status, 78.2% were estrogen receptor positive (ER+), 71.5% were progesterone receptor positive 
(PR+), and 61.7 were both ER+ and PR+. 
The mean number of hot flashes was 7.3 per 24 h. Vasomotor symptoms were reported to interfere with normal 
life in 78.5% of women. Previous HT-use was reported by 745 women (23.7%). 
Prior to study entry, patients underwent adjuvant radiotherapy (70.7%) and/or chemotherapy (70.2%), while 
adjuvant use of tamoxifen (74.6%), aromatase inhibitors (7.6%) and GnRH analogs (6.0%) also was reported. At 
randomization, many patients still used tamoxifen (66.2%), aromatase inhibitors (6.7%), chemotherapy (5.0%), 
or GnRH analogs (4.4%). 
Of the total of 3148 women enrolled, 739 had had a hysterectomy. Mean double-wall endometrial thickness was 
5.5 mm in tamoxifen users and 3.0 mm in other women. 
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Table 1 Population characteristics in the LIBERATE study at baseline 
Characteristics 
Number of subjects randomized  3148 
Age (years) Mean (S.D.) 52.6 (7.3) 
   ≤ 50 years of age n (%) 1282 (40.7) 
   > 50 years of age n (%) 1866 (59.3) 
Body mass index (kg/m2) Mean (S.D.) 27.0 (4.9) 
Weight (kg) Mean (S.D.) 70.5 (13.9) 
Height (cm) Mean (S.D.) 161.5 (6.8) 
Hot flushes per day (24 h) Mean (S.D.) 7.3 (5.9) 
Time since BC surgery (years) Mean (S.D.) 2.1 (1.3) 
Type of breast cancer surgery n (%)  
   Breast sparing  1346 (42.8) 
   Mastectomy  1802 (57.2) 
E receptor status n (%)  
   Positive  2181 (69.3) 
   Negative  609 (19.3) 
   Unknown  358 (11.4) 
P receptor status n (%)  
   Positive  1878 (59.7) 
   Negative  750 (23.8) 
   Unknown  520 (16.5) 
Lymph node status n (%)  
   Positive  1822 (57.8) 
   Negative  1322 (42) 
   Unknown  4 (0.1) 
Previous HT-use n (%) 744 (23.7) 
Relevant co-medications   
   Chemotherapy n (%)  
   Previous  2209 (70.2) 
   At randomisation  158 (5.0) 
GnRH analogs n (%)  
   Previous  188 (6.0) 
   At randomisation  137 (4.4) 
Tamoxifen n (%)  
   Previous  2348 (74.6) 
   At randomisation  2083 (66.2) 
Aromatase inhibitors n (%)  
   Previous  238 (7.6) 
   At randomisation  211 (6.7) 
E, estrogen; P, progestogen; GnRH, gonadotropin releasing hormone. 
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Table 2 Relevant characteristics in non-tamoxifen users vs. tamoxifen users 
Use of adjuvants at baseline  
No  
(n = 865) 
Tamoxifen  
(n = 2072) 
Aromatase inhibitors* 
(n = 211) 
Total  
(n = 3148) 
TVUS double wall endometrial 2.9 (1.5) 5.4 (4.7) 3.2 (1.9) 4.6 (4.1) 
thickness (mm) (mean (S.D.))     
Hot flashes per 24 h (mean (S.D.)) 6.8 (5.3) 7.4 (6.2) 7.8 (6.2) 7.3 (5.9) 
(Very) severe hot flashes (%) 32.5 35.1 43.2 34.8 
(Very) severe flashes/sweats 24.2 24.0 34.9 24.7 
interfering with normal life (%)     
(Very) severe palpitations (%) 7.3 4.6 7.8 5.6 
(Very) severe joint pain (%) 12.8 9.1 15.6 10.5 
(Very) severe dryness of vagina (%) 13.2 8.3 17.5 10.2 
(Very) severe incontinence (%) 1.9 1.5 1.5 1.6 
*Fourteen subjects also received tamoxifen within 14 days of baseline. 
 
Fig. 1. Study of population characteristics at baseline. 
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Fig. 2. Climacteric complaints at baseline. 
 
Discussion 
The LIBERATE study is currently the only ongoing randomized, double-blind controlled study seeking to 
provide information about the safety and efficacy of a potential treatment option for vasomotor symptoms in 
women with a history of breast cancer. Evidence from this large, multinational study is vital to determine 
whether or not tibolone is indeed equal to placebo with regard to breast cancer recurrence and hence to provide 
evidence-based advise for a group of breast cancer patients for whom there is a pressing need for a safe and 
effective treatment of vasomotor symptoms.5 Based on the data reported here, it can be expected that 
LIBERATE through its design, size and successful accrual of participants, will provide a sufficient basis for this 
evidence. The 3148 women were included in a relative short period of 2.5 years. Over 70% of women enrolled in 
the study were breast cancer Stage IIA or higher. In total 1830 women (58.1%) had a positive lymph node status 
in accordance with the assumptions for the power calculation and sample size estimate. The LIBERATE 
population is not an average early breast cancer population and many physicians would be highly reluctant to 
treat ER+, lymph node positive, tamoxifen using breast cancer patients with hormones. Therefore, non-
inferiority to placebo demonstrated in this population would be of large clinical significance. LIBERATE 
showed the feasibility of such a trial. Based on a thorough review of unblinded data (of in total 6371 women 
years of exposure and 7260 women years of trial participation), the Data and Safety Monitoring Board in its 6th 
meeting statement of 6 October 2006 recommended again that the LIBERATE trial continue with no alterations 
to the protocol or patient information sheet. 
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Presence of vasomotor symptoms was required at baseline. However, there were no criteria specified with regard 
to the number or severity of hot flashes. Several guidelines propose criteria that need to be fulfilled in order to 
show the efficacy of a treatment in managing vasomotor symptoms. Therefore, in addition to the overall sample, 
analyses of hot flashes will also focus on subgroups of highly symptomatic subjects according to EMEA26 and 
FDA guidelines.27 In addition, the LIBERATE study may also provide valuable information on overall survival, 
BMD and HRQL, important issues in this disease-free patient group of which 40% is younger than 51 years of 
age, and with a moderate to excellent prognosis. 
As menopausal symptoms can severely affect quality of life, it was decided to complement conventional efficacy 
evaluations with HRQL assessments in order to provide a comprehensive picture of the impact of symptoms and 
to assess the potential benefits of treatment. In addition to relief of vasomotor symptoms, tibolone has been 
reported to positively influence both mood and sexual well-being,14 and therefore possibly HRQL. Thus, also 
compliance to adjuvant cancer treatment could be increased and, therefore, overall survival. 
It is particularly important to ensure endometrial safety in women taking tamoxifen due to an increased risk of 
endometrial cancer. A well-known problem of performing TVUS in tamoxifen-treated women is a high 
incidence of apparent endometrial thickening and an associated increase in invasive procedures, most of which 
are not indicated.28-30 Measurement of endometrial thickness by TVUS in tamoxifen-treated women therefore 
appears not to be a reliable screening tool. In the LIBERATE study, TVUS was performed in tamoxifen-treated 
women at screening only in order to exclude endometrial polyps. As almost all endometrial carcinomas are 
detected after the occurrence of vaginal bleeding, both in tamoxifen users and in non-users,28-30 an endometrial 
biopsy was taken to exclude endometrial cancer, when significant vaginal bleeding occurred during the trial. 
Current evidence suggests that postmenopausal HT is associated with an increased risk of breast cancer, and that 
this risk is greater with combined HT8 than with estrogen alone.7,31 The Million Women Study also reported an 
increased risk of breast cancer with tibolone (relative risk, 1.45; 95% confidence interval, 1.25-1.67), although 
this was significantly (p < 0.0001) less than that with combined HT.7 However, it appears that the risks reported 
in this study may have been overestimated32-34 and this, combined with the relatively small numbers of women 
who were treated with tibolone (6%) and the potential for preferential prescribing25 probably implies that the 
current evidence is inconclusive. Another epidemiological study conducted in the UK, using the General Practice 
Research Database, revealed a similar number of women with breast cancer as the Million Women Study (7192 
vs. 7140 cases, respectively), but showed no increased risk with tibolone (relative risk, 1.02; 95% confidence 
interval, 0.78-1.33).35 However, this study still awaits appropriate publication. 
Because of the concerns about HT and breast cancer risk, and fears that HT might promote breast cancer 
recurrence, only a few studies, mostly small and observational in design, have been conducted to assess HT use 
in women with a history of breast cancer.9,10,36-38 With most observational studies on HT use in breast cancer 
survivors being reassuring, the need for prospective randomized clinical trials becomes evident. Marsden et al.39 
proved in a small pilot randomized trial, that such trials would be feasible. Unfortunately, two large open 
randomized trials that were designed to resolve some of the uncertainty were stopped prematurely.11,12 One of 
these, the HABITS (hormonal replacement therapy after breast cancer—is it safe?) study (only 434 women 
randomized), was stopped in December 2003 after a median follow-up of 2.1 years because the risk of 
recurrence was significantly higher amongst women receiving HT than amongst those with no menopausal 
therapy (relative hazard, 3.3; 95% confidence interval, 1.5-7.4).11 In contrast, the Stockholm trial (378 women 
randomized) revealed no evidence of an increased risk of recurrence in women treated with HT compared with 
untreated women after a median follow-up of 4.1 years (relative hazard, 0.82; 95% confidence interval, 0.35-
1.9).12 However, due to anticipated problems with recruitment and compliance, the trial was terminated 
prematurely. Possible reasons proposed for these conflicting findings included differences in the clinical 
characteristics of the patients, less use of adjuvant tamoxifen therapy in the HABITS trial and an attempt to 
minimize the use of progestogen in the Stockholm trial. 
At present, LIBERATE is the only randomized trial to provide an answer for breast cancer survivors with severe 
climacteric complaints, eagerly awaited both by patients and doctors. The successful accrual of 3148 women and 
the characteristics of the population at baseline as described here would allow for such an answer. 
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